© 2024 BioMarin. All rights reserved.

A dynamic cross-section of business, clinical and biotechnical expertise with a proven track record of providing rapid access to breakthrough therapeutics.

Under the leadership of our President and Chief Executive Officer Alexander Hardy, BioMarin’s executive management team includes accomplished leaders with deep and broad executive experience. Supported by a staff of approximately 3,000 employees worldwide, we are focused on delivering first-in-class and best-in-class therapeutics to patients with rare genetic diseases.

Our Pipeline

We maximize the impact of genetic innovation to develop transformative therapies.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

Learn More Our Pipeline